Corcept Change To Liabilities from 2010 to 2024

CORT Stock  USD 31.93  1.38  4.14%   
Corcept Therapeutics Change To Liabilities yearly trend continues to be comparatively stable with very little volatility. Change To Liabilities will likely drop to about 3.1 M in 2024. From the period from 2010 to 2024, Corcept Therapeutics Change To Liabilities quarterly data regression had mean square error of 18.1 T and mean deviation of  3,295,707. View All Fundamentals
 
Change To Liabilities  
First Reported
2000-12-31
Previous Quarter
9.2 M
Current Value
8.6 M
Quarterly Volatility
3.5 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Corcept Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Corcept Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 4.3 M, Selling General Administrative of 193.1 M or Research Development of 193.6 M, as well as many indicators such as Price To Sales Ratio of 6.62, Dividend Yield of 0.0 or PTB Ratio of 6.97. Corcept financial statements analysis is a perfect complement when working with Corcept Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Corcept Therapeutics Correlation against competitors.

Latest Corcept Therapeutics' Change To Liabilities Growth Pattern

Below is the plot of the Change To Liabilities of Corcept Therapeutics Incorporated over the last few years. It is Corcept Therapeutics' Change To Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Corcept Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Change To Liabilities10 Years Trend
Slightly volatile
   Change To Liabilities   
       Timeline  

Corcept Change To Liabilities Regression Statistics

Arithmetic Mean3,734,791
Coefficient Of Variation117.84
Mean Deviation3,295,707
Median1,851,000
Standard Deviation4,401,099
Sample Variance19.4T
Range18.5M
R-Value0.36
Mean Square Error18.1T
R-Squared0.13
Significance0.18
Slope358,577
Total Sum of Squares271.2T

Corcept Change To Liabilities History

20243.1 M
20235.5 M
20224.8 M
20211.6 M
20208.3 M
20191.9 M
20186.2 M

About Corcept Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Corcept Therapeutics income statement, its balance sheet, and the statement of cash flows. Corcept Therapeutics investors use historical funamental indicators, such as Corcept Therapeutics's Change To Liabilities, to determine how well the company is positioned to perform in the future. Although Corcept Therapeutics investors may use each financial statement separately, they are all related. The changes in Corcept Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Corcept Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Corcept Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Corcept Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Change To Liabilities5.5 M3.1 M

Pair Trading with Corcept Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Corcept Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corcept Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Corcept Stock

  0.8TOVX Theriva BiologicsPairCorr
  0.78PRGO Perrigo Company Buyout TrendPairCorr
  0.66ATXI Avenue TherapeuticsPairCorr
  0.51ANVS Annovis Bio Earnings Call TodayPairCorr
  0.43NEO NeoGenomicsPairCorr
The ability to find closely correlated positions to Corcept Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Corcept Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Corcept Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Corcept Therapeutics Incorporated to buy it.
The correlation of Corcept Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Corcept Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Corcept Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Corcept Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Corcept Stock Analysis

When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.